Navigation Links
CareFusion Reports First Quarter Fiscal 2012 Results
Date:11/7/2011

with the FDA and our failure to comply with the requirements of the amended consent decree may have an adverse effect on our business; and our success depends on our key personnel, and the loss of key personnel or the transition of key personnel, including our chief executive officer, could disrupt our business. The CareFusion news release and the information contained herein reflect management's views as of Nov. 7, 2011. Except to the limited extent required by applicable law, CareFusion undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.CAREFUSION CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF INCOME(UNAUDITED)Quarter Ended September 30,(in millions, except per share amounts)20112010Revenue

$

844

$

811Cost of Products Sold417398Gross Margin427413Selling, General and Administrative Expenses273272Research and Development Expenses3940Restructuring and Acquisition Integration Charges722Operating Income10879Interest Expense and Other, Net 2523Income Before Income Tax8356Provision for Income Tax1620Income from Continuing Operations6736Income from Discontinued Operations, Net of Tax-2Net Income

$

67

$

38Per Share Amounts:(1)Basic Earnings per Common Share:Continuing Operations

$

0.30

$

0.17Discontinued Operations

$

-

$

0.01Basic Earnings per Common Share

$

0.30

$

0.17Diluted Earnings per Common Share:Continuing Operations

$

0.30

$

0.17Discontinued Operations

$

-

$

0.01Diluted Earnings per Common Share

$

0.30

$

0.17Weighted-Average Number of Common Shares Outstanding:Basic223.8222.1Diluted226.3223.9____________1Earnings per share calculations are performed separately for each component presented.  Therefore, the sum of the per share components from th
'/>"/>

SOURCE CareFusion
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ERT Closes the Acquisition of the Research Services Division of CareFusion Corporation
2. Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011
3. InterMune Reports Third Quarter 2011 Financial Results and Business Highlights
4. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
5. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
6. Caliper Life Sciences Reports Third Quarter 2011 Results
7. Neurocrine Biosciences Reports Third Quarter 2011 Results
8. United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
9. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
10. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
11. ReportsnReports: Depression Therapeutics Market to Reach $10.9 Billion by 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... (PRWEB) August 22, 2014 “Our ... acknowledgement is a national disgrace. Furthermore, every governmental ... establishing the current, deplorable state of unorganized dysfunction ... great mistakes," to merely serve as a device ... extent of colossal failure(s) that have accumulated through ...
(Date:8/21/2014)... N.Y. , Aug. 21, 2014  BioSpecifics ... biopharmaceutical company developing first in class collagenase-based products ... or CCH) in the U.S. and XIAPEX ® ... significant results from a randomized, double-blind Phase 2a ... cellulite, or edematous fibrosclerotic panniculopathy. The results showed ...
(Date:8/21/2014)... PA & Rockville, MD (PRWEB) August 21, 2014 ... (ITI) is making progress in its development of ... to Japanese red cedar pollen. Phase IC studies began ... a real solution to hay fever. , The Japanese ... over 35 million people in Japan. Mountain Cedar pollen ...
(Date:8/21/2014)... for Molecular Medicine Finland (FIMM), University of Helsinki, ... "man and machine" decision support system for diagnosing ... in PLOS One scientific journal today, ... vision algorithms similar to those used in facial ... diagnostically most relevant areas. Tablet computers can be ...
Breaking Biology Technology:5 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4A novel 'man and machine' decision support system makes malaria diagnostics more effective 2
... June 3, 2010 Ben-Gurion University of the Negev students ... people maneuver around obstacles. The radar system incorporates a ... warn the blind of obstacles with audible alerts. The ... the depth of its surroundings, taken from two different angles ...
... HAYWARD, Calif. , June 3 Anthera Pharmaceuticals, Inc. ... diseases associated with inflammation and autoimmune disorders, today announced Colin Hislop ... of Anthera. Dr. Hislop replaces James E. Pennington , M.D., who ... , , ...
... June 3 Kendle (Nasdaq: KNDL ), ... it is ranked a top CRO to work with in ... only CRO to be ranked consistently among the top three ... annual U.S. and European site surveys conducted by CenterWatch, a ...
Cached Biology Technology:Ben-Gurion University students develop device to help blind manuever 2Anthera Pharmaceuticals Promotes Colin Hislop, M.D., to Chief Medical Officer 2Anthera Pharmaceuticals Promotes Colin Hislop, M.D., to Chief Medical Officer 3Anthera Pharmaceuticals Promotes Colin Hislop, M.D., to Chief Medical Officer 4Kendle Rated a Top CRO to Work with for Fourth Consecutive Year 2Kendle Rated a Top CRO to Work with for Fourth Consecutive Year 3
(Date:8/21/2014)... skin fungus linked to dandruff, eczema and other itchy, ... even further global reachesincluding Hawaiian coral reefs and the ... , A review in the scientific journal PLOS ... the fungi of the genus Malassezia in ... datasets from around the world. , University of Hawai,i ...
(Date:8/21/2014)... AWI geologist Juliane Mller the Fram Strait is a key ... of this passage between Greenland and Svalbard warm Atlantic water ... the west side cold Arctic water masses and sea ice ... Atlantic. A considerable portion of the Atlantic water cools here ... layers. The circulation of the water caused in this manner ...
(Date:8/21/2014)... A team of researchers at Louisiana Tech ... using affordable, consumer-grade 3D printers and materials ... contain antibacterial and chemotherapeutic compounds for targeted ... doctoral students and research faculty from Louisiana ... collaborated to create filament extruders that can ...
Breaking Biology News(10 mins):From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2Arctic sea ice influenced force of the Gulf Stream 2Arctic sea ice influenced force of the Gulf Stream 3Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3
... 2014 FASEB Science Research Conference focuses on structural virology ... the progression of events that are the virus lifecycle: ... exit. Virus assembly includes the process of constructing virions ... Knowledge on virus structure and assembly can be ...
... This FASEB Science Research Conference will focus on ... digestion and absorption with new translational emphasis on ... mechanisms of health maintenance and development of chronic ... dyslipidemia, intestinal failure and gastrointestinal inflammation. ...
... This FASEB Science Research Conference focuses on recent advances ... of this meeting is to promote the discovery and ... of protein structure, to facilitate the application of methods ... to biological problems, and to support and foster the ...
Cached Biology News:
Estrogen Receptor (ER) Competitor Assay Kits Green for Estrogen Receptors-alpha and -beta (ER-Alpha and ER-Beta) are ideal for screening novel estrogen receptor binding compounds and endocrine disrup...
Antibodies were affinity purified using epitopes specific to Alpha4 immobilized on solid support....
Prepared in distilled water....
in vitro Translation, Accessory Products...
Biology Products: